In collaboration with the University Maternity and Gynecological Clinic B' of "Aretaio" Hospital, the Radiology Laboratory of the "Alexandra" Hospital and the Cytology Laboratory of the "Attikon" Hospital.

There exist effective population screenings and prevention programs for two types of gynecological cancer: Breast cancer and cervical cancer. For breast cancer, the screening test is a mammography and for cervical cancer it is the Pap smear test and the HPV DNA test.

Breast cancer: It is estimated that 1 in 8 women worldwide will experience breast cancer at some stage of their life. In Europe, 60% of cases of breast cancer are diagnosed at an early stage. The corresponding figure in Greece is only 5%. These data demonstrate how deficient the relative information among Greek women is. Breast cancer is the 2^or The most common cause of cancer death in women (after lung cancer). Early diagnosis and modern breast cancer treatments offer good quality of life and very good survival (89.4% 5-year survival and 78% 10-year survival). It is estimated that one-third of breast cancer cases can be prevented by mammography screening.

The American Cancer Society guidelines (JAMA 2015) propose annual mammogram testing for the ages of 45-54 and screened every two years from 55 years onwards. Breast palpation is not recommended as a screening test in women who are not at an increased risk for breast cancer.

Breast cancer screening will be done via digital mammography on the mobile unit by a technologist and the results will be centrally controlled at the HYGEIA Health Center.

Women with suspicious findings will be referred directly to the associated Hospitals and the University Clinics that will participate in the gynecological cancer prevention program. The Coordinating Committee of the Program will be responsible for the safe referral.

Cervical Cancer: Cervical cancer is the most common cause of death from cancer in women in developing countries and the third most common type of cancer after lung and breast cancer in women worldwide. Cervical cancer is a disease that can be prevented and treated as long as it is diagnosed in time. Over 80% of women diagnosed with cancer at an early stage are fully cured. The main cause of cervical cancer is human papillomavirus infection (HPV), and in particular the infection by about 15 types of the specific virus (there are over 100 types). The Pap test and the HPV DNA test will be performed by gynecologists and midwives on the mobile unit, and the Diagnostic Cytology Laboratory of the "Attikon" Hospital (Director, Professor Karakitsos) will examine all Pap test and HPV DNA tests. More specifically, the ASCCP protocol will apply, according to which:

1. A Pap smear test by Thin Prep will be performed on women aged 21 to 60 years.
2. In women aged 31-60 years, as a reflex test, an HPV DNA test will be performed regardless of pathology
3. On Positive Pap smear test and HPV DNA tests, the women will be referred for colposcopy.
4. In the case of a negative Pap test and a positive HPV DNA test, an HPV mRNA test and p16 will be performed as a reflex test. If one of the two tests is positive, then the woman will be immediately referred for colposcopy.

The Coordinating Committee of the Program will be responsible for the safe referral.

THE DURATION OF THE GYNECOLOGICAL PREVENTION TEST IS SET AS HALF AN HOUR/ WOMAN AND RE-EVALUATION IS ESTIMATED IN 2-5 YEARS.